Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Novartis
Novartis
AstraZeneca
University of Pittsburgh
Pharmassist Ltd
Johns Hopkins University
Simons Searchlight
Sanford Health
Assistance Publique - Hôpitaux de Paris
Novartis
Novartis
AstraZeneca
British Columbia Cancer Agency
Fudan University